Annexon (ANNX) vs Ardelyx (ARDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Annexon (ANNX) has outperformed Ardelyx (ARDX) over the past year, gaining 27.0% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -81.8% for ANNX. Ardelyx is the larger company by market cap ($844.3 million vs $758.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | ARDX |
|---|---|---|
| Share price | $4.00 | $3.27 |
| Market cap | $758.32M | $844.27M |
| 1-day change | -0.25% | +0.31% |
| YTD return | -20.32% | -43.91% |
| 1-year return | +26.98% | -35.38% |
| 5-year return | -81.82% | +202.78% |
| Forward P/E | — | 11.26 |
| EPS (TTM) | $-1.13 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $8.40 |
| 52-week low | $2.54 | $3.18 |
| Distance from 52-week high | -44.29% | -61.07% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +294.50% |
| Average volume | 3.11M | 4.17M |
| Shares outstanding | 189.58M | 258.19M |
| Employees | 92 | 489 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed ARDX by 62.4 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
ANNX vs ARDX FAQ
Which is bigger, Annexon or Ardelyx?
Ardelyx (ARDX) is larger, with a market capitalization of $844.27M compared with $758.32M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or ARDX?
ANNX returned +26.98% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Ardelyx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.